Wave Life Sciences (WVE) Return on Capital Employed (2015 - 2026)
Wave Life Sciences (WVE) posted Return on Capital Employed of 35.08% for Q1 2026, up 43.83% on a QoQ basis from 62.45% in Q4 2025, and up 1891.0% year-over-year from 1.76% in Q1 2025.
Wave Life Sciences (WVE) Return on Capital Employed (2015 - 2026) Analysis & Trends
Wave Life Sciences' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 35.08% for Q1 2026.
- Quarterly Return on Capital Employed rose 1891.0% year-over-year to 35.08% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35.08% (up 1891.0% YoY) and the FY2025 annual result came in at 53.81%, up 68.0% from the prior year.
- Return on Capital Employed was 35.08% for Q1 2026 at Wave Life Sciences, up from 62.45% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 35.08% in Q1 2026 and bottomed at 208.6% in Q1 2023.
- A 5-year average of 104.7% and a median of 94.52% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 11408 bps — and 2024, when it jumped 12773 bps.
- Wave Life Sciences' Return on Capital Employed stood at 176.05% in 2022, then grew by 24 bps to 133.34% in 2023, then surged by 66 bps to 45.17% in 2024, then slumped by 38 bps to 62.45% in 2025, then soared by 44 bps to 35.08% in 2026.
- Business Quant data shows WVE's Return on Capital Employed at 35.08% in Q1 2026, 62.45% in Q4 2025, and 84.46% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Wave Life Sciences | 1.16 Bn | 612.38 Mn | - | -35.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -35.08% |
| Dec 31, 2025 | -62.45% |
| Sep 30, 2025 | -84.46% |
| Jun 30, 2025 | -78.45% |
| Mar 31, 2025 | -53.99% |
| Dec 31, 2024 | -45.17% |
| Sep 30, 2024 | -134.64% |
| Jun 30, 2024 | -171.10% |
| Mar 31, 2024 | -80.87% |
| Dec 31, 2023 | -133.34% |
| Sep 30, 2023 | -80.78% |
| Jun 30, 2023 | -125.66% |
| Mar 31, 2023 | -208.60% |
| Dec 31, 2022 | -176.05% |
| Sep 30, 2022 | -116.61% |
| Jun 30, 2022 | -98.19% |
| Mar 31, 2022 | -94.52% |
| Dec 31, 2021 | -91.01% |
| Sep 30, 2021 | -70.55% |
| Jun 30, 2021 | -83.25% |